摘要
近年来,新型直接抗病毒药物(DAAs)药物研发取得了突破性进展,使其在抗HCV过程中具备高SVR率、广泛基因型谱、治疗周期短以及耐药率低等优点。但随着新型抗病毒药物在临床中的广泛应用,已发现多个相关耐药位点直接影响抗HCV的疗效,本文针对新型DAAs药物(包括NS3/4A蛋白酶抑制剂、NS5A蛋白抑制剂及NS5B聚合酶抑制)及其相关耐药位点进行总结。
In recent years, the development of direct-acting antiviral agents(DAAs) has made a breakthrough and had a variety of advantages of a high SVR rate, a wide genotype spectrum, a short treatment cycle and a low resistance rate in the treatment for HCV infection process. With the development of new antiviral drugs in clinical application, it has been found that the efficacy of treatment for HCV infection was directly affected by some related resistance loci. In this paper, the new DAAs drugs(including NS3/4A protease inhibitors, NS5 A inhibitors and NS5 B polymerase inhibition) and the related drug resistance loci were summarized.
出处
《中华实验和临床感染病杂志（电子版）》
CAS
2016年第5期534-540,共7页
Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition)
基金
江苏省"科教兴卫"医学重点人才培养基金(No.RC2011117)
江苏省"六大人才高峰"项目(No.2011-WS-068)
关键词
肝炎病毒
丙型
基因型
DAAs抑制剂
耐药位点
Hepatitis C virus
Genotype
Direct-acting antiviral agents inhibitor
Resistance mutations
